INT65578

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.26
First Reported 1995
Last Reported 2010
Negated 2
Speculated 1
Reported most in Body
Documents 8
Total Number 10
Disease Relevance 6.81
Pain Relevance 2.20

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (GFAP) extracellular matrix organization (GFAP) cytoplasm (GFAP)
Anatomy Link Frequency
macrophage 1
nerve 1
lens 1
LGN 1
microglia 1
GFAP (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 2 100.00 Very High Very High Very High
Neuropathic pain 2 99.36 Very High Very High Very High
Morphine 10 98.40 Very High Very High Very High
cocaine 3 97.96 Very High Very High Very High
Ventral tegmentum 6 97.08 Very High Very High Very High
Opioid 1 94.32 High High
Spinal cord 74 89.56 High High
Nucleus accumbens 4 84.88 Quite High
Dopamine 4 83.04 Quite High
Neurobehavioral 14 82.72 Quite High
Disease Link Frequency Relevance Heat
Neuropathic Pain 2 99.36 Very High Very High Very High
Adhesions 3 98.42 Very High Very High Very High
Optic Nerve Injuries 70 96.64 Very High Very High Very High
Ocular Hypertension 142 96.52 Very High Very High Very High
Targeted Disruption 24 96.24 Very High Very High Very High
Hepatitis C Virus Infection 378 95.20 Very High Very High Very High
Anaplasia 1 94.16 High High
Keloid Scars 22 93.80 High High
Acquired Immune Deficiency Syndrome Or Hiv Infection 146 91.76 High High
Necrosis 9 88.40 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Indeed, as seen for chronic morphine and cocaine treatments, we show here that chronic ethanol treatment increased levels of tyrosine hydroxylase and glial fibrillary acidic protein immunoreactivity, and decreases levels of neurofilament protein immunoreactivity, in the VTA.
Regulation (immunoreactivity) of glial fibrillary acidic protein associated with ventral tegmentum, cocaine and morphine
1) Confidence 0.26 Published 1995 Journal Synapse Section Abstract Doc Link 8869159 Disease Relevance 0 Pain Relevance 0.81
Both cellular components expressed non-polysialylated neural cell adhesion molecule (NCAM)-L species, and several overlapping areas of synaptophysin and GFAP immunoreactivity were present.
Regulation (immunoreactivity) of GFAP in neural associated with adhesions
2) Confidence 0.26 Published 2006 Journal Pathol. Res. Pract. Section Abstract Doc Link 16413693 Disease Relevance 1.19 Pain Relevance 0.10
GFAP and MAC-1 immunoreactivities were elevated in spatial register with the treated eye layers of the LGN and V1 in ONT animals.
Regulation (immunoreactivities) of GFAP in LGN associated with optic nerve injuries
3) Confidence 0.22 Published 2009 Journal Molecular Vision Section Abstract Doc Link PMC2773743 Disease Relevance 1.25 Pain Relevance 0.10
High power images of GFAP and MAC-1 immunoreactivity (Figure 1D-I, Figure 2D-I, Figure 3D-I, and Figure 4D-I) were taken using a 100× oil objective lens.
Regulation (immunoreactivity) of GFAP in lens
4) Confidence 0.22 Published 2009 Journal Molecular Vision Section Body Doc Link PMC2773743 Disease Relevance 0 Pain Relevance 0
Morphological analysis at day 14 post-implantation disclosed increased immunoreactivity of GFAP, an astrocyte marker, and Iba-1, a microglia/macrophage marker, in the right striatum of Vpr-transgenic mice receiving HCV core protein implantation (Figure 7Aiv and v).
Regulation (immunoreactivity) of GFAP in macrophage associated with targeted disruption and hepatitis c virus infection
5) Confidence 0.14 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2943470 Disease Relevance 1.81 Pain Relevance 0.10
Further, biochemical analyses supplement stereological data and demonstrate no changes in Fibronectin, Versican, GFAP, NG2, and PE-CAM1 protein expression at 2 weeks post-transplant.
Neg (no) Regulation (changes) of GFAP
6) Confidence 0.12 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2690693 Disease Relevance 0.15 Pain Relevance 0
Additionally, biochemical protein analysis supplemented our stereological quantification and demonstrated no changes in protein expression levels of Fibronectin, NG2, Versican, GFAP, and PE-CAM1 at 2 weeks post-transplant.
Neg (no) Regulation (changes) of GFAP
7) Confidence 0.12 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2690693 Disease Relevance 0.43 Pain Relevance 0
Morphological analysis at day 14 post-implantation disclosed increased immunoreactivity of GFAP, an astrocyte marker, and Iba-1, a microglia/macrophage marker, in the right striatum of Vpr-transgenic mice receiving HCV core protein implantation (Figure 7Aiv and v).
Regulation (immunoreactivity) of GFAP in microglia associated with targeted disruption and hepatitis c virus infection
8) Confidence 0.05 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2943470 Disease Relevance 1.81 Pain Relevance 0.10
In the present study, we aimed to examine the potential protective effect of yohimbine, a alpha(2)-adrenoceptor antagonist, against glial fibrillary acidic protein (GFAP) alterations elicited by chronic morphine treatment.
Spec (examine) Regulation (effect) of acidic protein associated with antagonist and morphine
9) Confidence 0.04 Published 2005 Journal Neurosci. Lett. Section Abstract Doc Link 15936527 Disease Relevance 0.08 Pain Relevance 0.70
Rats subjected to 8 weeks of unilateral L4/L5 nerve ligation (a model of neuropathic pain) showed leakage of albumin, up-regulation of glial fibrillary acidic protein (GFAP) immunoreaction, and abnormal cell reaction.
Regulation (regulation) of acidic protein in nerve associated with neuropathic pain
10) Confidence 0.01 Published 2006 Journal Acta Neurochir. Suppl. Section Abstract Doc Link 16671481 Disease Relevance 0.10 Pain Relevance 0.29

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox